Latest United Therapeutics Corporation Stories
SILVER SPRING, Md., April 25, 2013 /PRNewswire/ -- Total Revenues of $245.1 million Earnings per Share of $1.24 per Basic Share or $1.19 per Diluted Share Earnings Before Non-Cash Charges of $2.76 per Basic Share, or $2.65 per Diluted Share United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the first quarter ended March 31, 2013. "I am pleased that our first quarter 2013 results were solid, providing a strong foundation for continued growth,"...
SILVER SPRING, Md., April 18, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its first quarter 2013 financial results before market open on Thursday, April 25, 2013. United Therapeutics will host a half-hour teleconference on Thursday, April 25, 2013, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference...
SILVER SPRING, Md., March 25, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it received a second complete response letter from the United States Food and Drug Administration (FDA) declining to approve its new drug application (NDA) for treprostinil diolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension (PAH). Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United...
- Total Annual Revenues of $916.1 million SILVER SPRING, Md., Feb. 26, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2012. "Our excellent annual results reflect both our leadership in pulmonary hypertension medicines and our discipline in focusing company resources on transformative growth opportunities," noted Martine Rothblatt, Ph.D., United Therapeutics' Chairman and...
SILVER SPRING, Md., Feb. 19, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its fourth quarter and annual 2012 financial results before market open on Tuesday, February 26, 2013. United Therapeutics will host a half-hour teleconference on Tuesday, February 26, 2013, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the...
SILVER SPRING, Md., Feb. 14, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for treprostinil diolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension. The FDA classified the resubmission as a complete, class 1 response to FDA's October 23, 2012 complete response letter and the FDA...
SILVER SPRING, Md., Feb. 4, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that its Board of Directors authorized the repurchase of up to an additional $420 million of the company's common stock. This program will become effective on March 4, 2013, and will remain open for up to one year. Purchases may be made in the open market or in privately negotiated transactions from time to time as determined by United Therapeutics' management and in...
SILVER SPRING, Md., Nov. 1, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2012. "It is certainly gratifying to see us closely approach, for the first time, a revenue run rate of one billion dollars per year," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "Our free cash flow enables us to continue investing in new therapies such as...
SILVER SPRING, Md., Oct. 25, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its third quarter 2012 financial results before market open on Thursday, November 1, 2012. United Therapeutics will host a half-hour teleconference on Thursday, November 1, 2012, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference...
SILVER SPRING, Md., Oct. 23, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it received a complete response letter from the United States Food and Drug Administration (FDA) declining to approve its new drug application (NDA) for treprostinil diethanolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension (PAH). The FDA letter questioned the clinical importance of the 6 Minute Walk Distance...
